Hair Loss
Conditions
Interventions
Group 1:Use placebo
Group 2:Use LT010 three times a week (for three consecutive days) and once a week thereafter.
Group 3:Use LT010 three times in the first week of every four weeks (for three consecutive days), and do not administer medication at other times
Group 4:Using LT010, three times in the first week of every four weeks (for three consecutive days), and once a week thereafter
Group 5:Use H-dose LT010, three times in the first week of every four weeks (for three consecutive days), and do not administer the remaining time
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
Male
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1) Healthy male aged 18-60; 2) Hamilton-Norwood grade IIIvetex, IV, and V participants with a clinical diagnosis of androgenic alopecia; 3) No special hairdressing treatment such as hair dyeing, perming and styling in the past 1 month; 4) Be willing to maintain the same style, color, and length of hair during the study period, without using special hair care products or hair treatments; 5) Consent to follow the trial treatment protocol and visit plan, to enroll voluntarily, and to sign a written informed consent.
Exclusion criteria
Exclusion criteria: 1) Those with other types of alopecia, such as alopecia areata or diffuse alopecia areata, syphilis alopecia, cicatricial alopecia, malnutrition, and chemotherapy/radiation-induced alopecia; 2) Participants with scalp skin diseases that affect the evaluation of efficacy, scalp trauma or other scalp skin lesions that require topical medication, such as fungal or bacterial infections, severe seborrheic dermatitis, scalp psoriasis, contact dermatitis, severe folliculitis, or scalp atrophy; 3) Those who have undergone hair transplant therapy; 4) Those who have used cosmetics, health care products or other products with anti-hair loss or hair growth effects in the past 6 months; 5) Participants with systemic diseases such as cardiovascular, endocrine or metabolic diseases, and patients with immunodeficiency or autoimmune diseases; 6) Being treated for asthma or other chronic respiratory diseases, or suffering from infectious disease; 7) Suffering from mental illness or mental illness; 8) Highly sensitive individuals; 9) Those who had participated in previous research or other clinical trials within 6 months; 10) Those who have received anti-cancer chemotherapy in the past 6 months; 11) Those who were assessed clinically unsuitable for trial participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall hair density;Local hair density; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life;Safety assessment;Satisfaction score; | — |
Countries
China
Contacts
Public ContactLi Li
West China Hospital, Sichuan University
Outcome results
None listed